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Abstract: Osteosarcoma is a rare type of cancer associated with a poor clinical outcome.
Even though the pathologic characteristics of OS are well established, much remains to
be understood, particularly at the molecular signaling level. The molecular mechanisms
of osteosarcoma progression and metastases have not yet been fully elucidated and
several evolutionary signaling pathways have been found to be linked with osteosarcoma
pathogenesis, especially the hedgehog signaling (Hh) pathway. The present review
will outline the importance and targeting the hedgehog signaling (Hh) pathway in
osteosarcoma tumor biology. Available data also suggest that aberrant Hh signaling
has pro-migratory effects and leads to the development of osteoblastic osteosarcoma.
Activation of Hh signaling has been observed in osteosarcoma cell lines and also in
primary human osteosarcoma specimens. Emerging data suggests that interference with
Hh signal transduction by inhibitors may reduce osteosarcoma cell proliferation and tumor
growth thereby preventing osteosarcomagenesis. From this perspective, we outline the
current state of Hh pathway inhibitors in osteosarcoma. In summary, targeting Hh signaling
by inhibitors promise to increase the efficacy of osteosarcoma treatment and improve
patient outcome.
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1. Introduction
Osteosarcoma (OS) is a highly malignant bone tumor which frequently leads to patient death due to
pulmonary metastasis, in spite of conventional chemotherapy and surgical excision of the primary tumor.
The survival rate is estimated to be around 60%–80% in patients treated with multidrug chemotherapy
and local control interventions [1]. Most conventional OS are localized to the metaphysis of the long
bones adjacent to the growth plates where elongations of bones are active especially during the puberty
stages. Approximately 1,000 cases of OS are reported in the USA each year and the greatest incidence
rate of OS is in children and adolescents. OS arises from the malignant transformation of mesenchymal
cells which differentiate towards formation of osteoid and bone. Most patients with newly diagnosed
OS present with localized disease but unfortunately 15%–30% of the patients already have metastases
detectable at the time of diagnosis. In OS, the most common site of metastasis is the lung which
comprises more than 85% of metastatic disease, with bone being the second most common site of distant
disease [2].
Apart from treatment modalities like surgery, chemo- and radiation therapy there are no effective,
alternative therapies for the treatment of malignant OS and as such, the development of novel therapeutic
strategies is urgently required. Aberrant activation of Hedgehog (Hh) signaling contributes to tumor
aggressiveness, affecting key tumorigenic processes such as proliferation, invasion and progression of
cancer cells [3]. Recently, it was shown that the Hh signaling pathway is involved in the pathogenesis of
OS [4–6]. Therefore, inhibitors targeting Hh signaling have attracted significant attention as novel,
molecularly targeted drugs. Hh signaling components including Patched (PTCH) and Smoothened
(SMO) have been detected in almost 70% of OS specimens [5] and consequently, Hh signaling may play
a critical role in the pathogenesis of OS. To reduce therapy side effects a desirable approach would be
direct targeting of cancer signaling pathways. Translational studies are actively assessing the inhibitory
activities of small molecule inhibitors of Hh pathway as promising anti-cancer agents. In this review, we
summarize the development of inhibitors to treat OS, targeting the Hh signaling pathway.
1.1. Hh Signaling Pathway
The Hh pathway acts as an organizer for embryonic development, patterning, growth control and
mediates morphogenesis [7]. In recent years, the Hh signaling pathway has emerged as a critical
determinant of cancer initiation, progression and metastasis of many types of cancers [8,9]. Hh pathway
is necessary for early embryogenesis and eventually ceases, however, in many types of cancers, including
OS, the signaling is re-activated [4,9]. Therefore, the regulation of Hh signaling in OS is important.
Three ligands have been identified in Hh signaling; Sonic Hedgehog (SHh), Indian Hedgehog (IHh) and
Desert Hedgehog (DHh) [7,8]. In addition, 12-transmembrane Patched proteins (PTCH1 and PTCH2),
the 7-transmembrane protein, smoothened (SMO) and the 5-zinc-finger transcription factors, GLI1,
GLI2 and GLI3 (glioma-associated oncogene homologs) are also identified [10,11]. Canonical Hh
signaling involves the binding of one of the ligands to the transmembrane receptor PTCH1 [12]. The
binding of Hh ligand in PTCH1 relieves G-protein coupled receptor-like protein SMO. After SMO is
relieved by Hh ligands it leads to downstream activation of the transcription factors known as GLI family
zinc finger proteins (GLI) by suppressor of fused (SUFU) and kinesin family member 17 (KIF17) [13]
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(Figure 1). Mutual interaction of SMO and the GLI proteins are believed to occur in the primary cilium,
and it is hypothesized that cells without primary cilia cannot respond to Hh ligand through the canonical
pathway [14]. In the absence of Hh ligands, PTCH inhibits SMO and rejects its entry to the cilium
where it is believed to inhibit various protein kinases like PKA, GSK-3b and CK1 [15]. As a result
of this, GLI proteins in complex with SUFU are phosphorylated by protein kinases which results in
proteolytic cleavage where GLI-2 is degraded to repressor GLI2-R, GLI-3 is degraded to GLI3-R while
GLI1 remains in full length. Typical Hh target genes are those that regulate the transcription of the
Hh responsive genes by themselves which include the components of the pathway PTCH and GLI1.
Other target genes include specific transcription factors such as cyclin D1 (CCND1), BMI1 polycomb
ring finger (BMI1), B-cell CLL/lymphoma 2 (BCL2), and vascular endothelial growth factor (VEGF)
etc. [16]. The Hh signaling pathway is unique as most of the components consist of both oncogenes as
well as tumour suppressor genes.
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Of all the components of Hh signaling, GLI1 gene is a unique as it has no reported somatic mutations 
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motility and invasion as reported in glioblastoma and breast cancers [23,25]. tGLI1 is reported to 
associate with VEGF-A gene promoter leading to its activation thereby provoking angiogenesis [25]. 
The ability of tGLI1 to activate cancer-mediating genes like CD24, VEGF-A, MMP-2, and MMP-9 [25,26] 
make it more potent transcriptional regulator than GLI1 or GLI1ΔN. 
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Of all the components of Hh signaling, GLI1 gene is a unique as it has no reported somatic mutations
while other components of the pathway including PTCH, SMO, Suppressor of Fused SUFU, GLI2, and
GLI3 hav mutations [17–22]. Howe e , GLI1 transcripts u de go alternative splicing leading to the
synthesis of an N-terminal deletion variant (GLI1∆N) [23] and truncated GLI1 variant (tGLI1) [24].
GLI1∆N variant is similar to GLI1 in which it also targets the same genes of GLI1. The expression
patterns of GLI1∆N differ from that of tGLI1 in that GLI1∆N is expressed in normal and cancerous
tissues similar to GLI1 [23]. However, tGLI1 variant is expressed only in tumour cells and tissues,
but undetectable in normal tissues [25]. The difference between tGLI1 variant and GLI1 is 41 amino
acids and since there is only minute difference in size between them indicate the possibility that some
of the previous functions attributed to GLI1 may have been due to tGLI1. tGLI1 expression influence
cell motility and invasion as reported in gl oblastoma and breast cancers [23,25]. tGLI1 is reported to
associate with VEGF-A gene promoter leading to its activation thereby provoking angiogenesis [25]. The
ability of tGLI1 to activate cancer-mediating genes like CD24, VEGF-A, MMP-2, and MMP-9 [25,26]
make it more potent transcriptional regulator than GLI1 or GLI1∆N.
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In Hh signaling, mutations and loss of heterozygosity (LOH) in PTCH1, with most of the mutations in
SMO are reported [27]. More than 90% of basal cell carcinomas (BCCs) harbour mutations in SMO [28].
Atwood et al. identified SMO mutations in 50% of resistant BCCs and showed that these mutations
maintain aberrant Hh signaling even in the presence of SMO inhibitors. In some of the cancers active
SMO mutant proteins fail to co-localize with PTCH1 thereby allowing the activation of the pathway
independently of Hh signaling [29]. Several studies have been reported that activation of Hh signaling
is also caused due to the mutations in SMO gene. Mutations in SMO are frequent in ameloblastomas
of the maxilla caused by substitution of amino acid (Leu412Phe) [30]. A somatic missense mutation
in SMO, caused by substitution of an amino acid in the seventh transmembrane domain (Trp535Leu), a
site predicted to disrupt G-protein coupling, cause SMO activation [21]. Therapeutic challenges remain
where tumors acquire resistance to SMO antagonists, and also in cases where signaling is driven by
active SMO mutants that exhibit reduced sensitivity to these compounds.
1.2. Hh Signaling and Its Induction of Malignancy in Osteosarcoma
Several evolutionary signaling pathways, such as Hh, Notch, Wnt and BMP-TGF beta-activin are
involved in the proper development of normal bone. It is also becoming increasingly clear that these
pathways can have a crucial role in many types of cancer. Of those signaling pathways, most of the
studies are now focused on Hh signaling in OS pathogenesis [31], rendering the inhibition of this pathway
as an interesting approach to control disease progression. Mohseny et al. reported that activation of Hh
pathway varied among various OS cell lines analysed and did not correlate with the patient survival [32].
However, Lo et al. analysed Hh pathway genes in 43 human primary high-grade OS samples and
determined that expression levels of genes encoding IHH, PTCH1 and GLI genes but not SMO were
higher in tumour specimens [5]. Ligand-dependent activation (IHH-PTCH1 co-expression) and ligand
independent (SMO, PTCH1, GLI) might lead to Hh stimulation in OS. Presently, this ligand-dependent
pathway is thought to be the major mechanism underlying Hh signaling activation. Moreover, the high
levels of IHh may lead to larger tumor size, a prognostic factor of OS thereby indicating that activation of
Hh signaling is required for OS progression [5]. Among the Hh components, recent studies have shown
that SMO and GLI activation are important components in the progression of OS. Hirotsu et al. analysed
the transcripts of Hh genes in OS cell lines (NHOst, 143B, HOS, MG63 and NOS-1) and determined that
SHh, DHh, PTCH1, SMO, GLI1 and GLI2 were overexpressed. However, only SMO, PTCH1, and GLI2
transcripts were over-expressed in human OS biopsy specimens [4]. One of the interesting observations
was the downregulation of GLI1 and upregulation of GLI2 in human OS biopsy specimens. The authors
hypothesized that the GLI1 promoter is inactivated in human OS by epigenetic modification and that
Hh pathway activity downstream of SMO is mediated only by GLI2. A recent article by Kitamoto et al.
showed that the high expression levels of GLI2 correlated with lung metastasis and has poor clinical
outcome in mice [33] but there was no correlation between the location of the OS and GLI2 expression.
Since the sample size used in the study was low the relationship between GLI2 expression and prognosis
could not be determined. Nagao et al. demonstrated that GLI2 is involved in the migration, invasion
and metastasis by regulating the cell cycle genes in vitro [8]. The importance of Hh signaling in OS
was further revealed from the studies on knockdown of GLI2 in nude mice. Inoculation of 143B OS
cells transfected with GLI2- shRNA resulted in a significant reduction of tumour growth as compared
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with inoculation of 143B cells transfected with control shRNA. The silencing of GLI2 in nude mice
provided a statistically significant survival benefit [8]. Treatment using GLI-2 shRNA approach might be
a promising. Expression of GLI2 also correlates with poor outcome in OS patients and siRNA silencing
of GLI2 increased the sensitivity of OS cell lines to chemotherapeutic drugs [34]. Moreover, microarray
expression profiles of normal, metastatic and non-metastatic OS patient samples further revealed that
SMO was expressed highly in metastatic OS [35]. Silencing of SMO by SMO shRNA inhibited OS
growth in xenograft mouse models and conferred a significant survival benefit [4]. Interaction between
Hh signaling components and other pathways have to be studied in more detail as aberrant Hh signaling
cannot alone initiate OS progression. Chan et al. generated an osteoblastic OS mouse model and found
that upregulated Hh signaling interacts with Yap1, the main effector of the Hippo tumor suppressor
pathway and H19, a long non-coding RNA. Since YAP1 expression is also upregulated in human OS
patient specimens, inhibition of Hh signaling and YAP1 together could present a significant therapeutic
value [36]. More evidence on mechanistic details of Hh signaling in OS are not discussed here in order
to focus on Hh signaling inhibitors in OS.
1.3. Hedgehog Signaling Inhibitors in Osteosarcoma
1.3.1. SMO Inhibitors
In recent years, Hh pathway drug discovery has been focused predominantly on targeting SMO,
central transducer of the Hh signaling. SMO is widely considered as the most druggable target in the
Hh signaling pathway. SMO inhibition alters transcription factors GLI1 and GLI2 to remain inactive,
which prevents the expression of tumor mediating genes within the Hh pathway. A recent review on Hh
inhibitors indicates the diversity of potential agents that are able to modulate the function of SMO. The
chemical action of some of the small molecule Hh pathway inhibitors has been described in detail [37].
Cyclopamine
The plant-derived compound cyclopamine first emerged as a potential drug that binds to SMO and
inhibits signal transduction to the nuclear target gene GLI. Warzecha et al. concluded that because
of limited potency and remarkable side effects of cyclopamine in OS it was not suitable for clinical
development [38]. Also, there was no significant difference in the pulmonary metastases in the
cyclopamine-treated mice group and the control group. Interestingly, studies by Hirotsu et al. showed
that cyclopamine exhibited greater potent effect in inhibiting proliferation via cell cycle regulation
in vitro. Cyclopamine decreased tumor growth in vivo but had side effects where mice experienced
loss of body weight and dehydration and eventually died [4]. Moreover, cyclopamine is chemically
unstable with poor solubility features [39]. These results in a mouse xenograft OS model system suggest
that cyclopamine may not be a better therapeutic option for OS.
IPI-926 (Saridegib)
Saridegib is an oral, semi-synthetic derivative of the alkaloid cyclopamine and has demonstrated
to exhibit potent anti-cancer activity in multiple preclinical animal models of cancer especially
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chondrosarcoma [40,41]. There is only one study that has been reported to determine the clinical efficacy
of saridegib in OS. Saridegib treatment in patient-derived xenografts (PDXs), generated from tumors of
patients with metastasis at diagnosis, reduced tumour growth by inhibiting the ligand-dependent Hh
signaling pathway [6]. One of the limitations of this study was the small sample size and the presence of
tumor heterogeneity. A larger cohort would be required to determine the efficacy of this drug in OS.
GDC-0449 (Vismodegib)
Vismodegib, a second generation cyclopamine, is a 2-arylpyridine molecule that blocks the activation
of SMO. Considerable advantages over cyclopamine have been observed with better aqueous and acid
stability. It is the first drug approved by the Food and Drug Administration (FDA) for the treatment
of locally advanced basal cell carcinoma (BCC) that cannot be removed by either surgical resection or
treated with radiation [42]. There is an ongoing Phase I and II clinical trial by the National Cancer
Institute to determine the side effects and optimal dose of vismodegib in extra-skeletal and metastatic
OS (ClinicalTrials.gov Identifier: NCT01154452). Kitamoto et al. showed that combination therapy
of vismodegib, ATO (arsenic trioxide) and GANT61 (GLI inhibitor) at low concentrations prevented
migration and metastasis of OS cells. Moreover, ATO and vismodegib significantly inhibited the
metastasis of OS to the lung which suggested that the combined administration of ATO and vismodegib
in xenografts might be effective for the treatment of OS metastasis [33].
LDE225 (Erismodegib)
Erismodegib, a SMO antagonist, induces G1 cell cycle arrest and apoptosis in many of the cancers [43].
There is an ongoing clinical trial to determine the efficacy of this drug in OS (ClinicalTrials.gov
Identifier: NCT01154452) in a pediatric phase I study.
1.3.2. GLI Inhibitors
GLI transcription factors are critical mediators of the Hh signaling pathway and their aberrant
activation might induce tumour cell proliferation and invasion. The Hedgehog-GLI signaling pathway
is active in many cancers and is known to contribute to the growth and survival of human OS cells [8].
The expression of GLI2 has been shown to be highly elevated in OS patients and that GLI2 could be
considered as a new therapeutic target for OS metastasis [34]. The following are the GLI inhibitors
which are found to be effective in controlling OS.
Arsenic trioxide (ATO)
ATO (As2O3) is an FDA-approved drug used for the treatment of patients with acute promyelocytic
leukemia (APL) [44]. ATO directly binds to GLI1 and GLI2 and inhibits its transcriptional activity and
deceases the expression of endogenous GLI target genes [45]. Tumour caused by intradermal inoculation
of 143B cells in nude mice were significantly reduced on daily treatment with ATO and provided a
significant survival benefit. Moreover, the number of apoptotic cells was also significantly increased in
ATO-treated tumors [46]. Li et al. used ATO which was incorporated in the magnetic nanoparticles
and encapsulated by poly lactic acid in vivo where MG63 OS cell lines were s.c injected into the mice.
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Tumour volume was significantly decreased in the nanoparticle encapsulated ATO treated group and the
inhibitory effect was similar to those treated with ATO alone [47]. Phase II trials have been completed
to determine the efficacy of this drug in OS (ClinicalTrials.gov Identifier: NCT00024258). Chiu et
al. demonstrated that combined treatment of radiation and ATO resulted in the increased induction
of autophagy and apoptosis via inhibition of the PI3K/Akt signaling pathway in OS cell lines [48].
In vitro studies using ATO in OS cell lines showed it inhibited migration and invasion by inactivating the
MAPK/ERK signaling pathway [49]. Taken together, ATO seems to be a promising drug for treatment
of OS but its effect on lung metastasis remains to be studied.
GANT
GLI activators Antagonists (GANT) which inhibits GLI-mediated transcription were discovered in a
screen-based assay [50]. Two Gli inhibitors which have been described are GANT 61 [51] and GANT
58 [52]. GANT 61 is one of the widely studied GLI inhibitor in OS [8]. The mechanism by which
GANT 61 and GANT 58 inhibit the Hh pathway at the GLI level is unknown. Current evidence suggests
that GANT 61 modifies GLI 1 and GLI 2 and prevents them from binding to the DNA promoter [50].
Studies on canine derived OS cells treated with GANT61 revealed an inhibition of cell proliferation
and reduced colony formation [53]. GLI2 has been reported to express highly in invasive OS cell lines
but not in non-invasive cells [54], hence targeting GLI2 with GANT 61 might be strategically possible.
Studies on treatment with GANT 61 in human OS cell lines revealed that GANT61 dose-dependently
inhibited proliferation but the growth of tumour remained unaffected on GANT 61 treatment group when
compared to mice who did not receive the drug [8]. Since GLI 2 is involved in bone development [55,56],
possible side effects for using GANT 61 in therapy may include bone defects, especially in children.
Currently, no clinical trials are being performed to test the efficacy of GANT61 in OS patients.
2. Conclusions
In this review, we have summarized the involvement of Hh signaling and its inhibitors for potential
therapy in OS. The Hh signaling pathway might represent a valid therapeutic target in OS. Further,
this pathway is activated in the progression of the disease and both ligand-dependent and independent
inhibitors are effective. Hh signaling inhibitors are found to be effective in cancers like BCC and
meduloblastoma where Hh signaling is constitutively activated and administration of Hh inhibitors as
a single agent in those cancers are already used as first line therapy. Within the different classes of
Hh inhibitors, recent drug development has focused on SMO inhibitors in controlling OS progression.
Despite the fact that a lot of Hh pathway inhibitors have been developed, none of them has yet
successfully reached the clinic for the treatment of OS. However, appropriate combination therapy with
other signaling inhibitors might be required for clinical trials since the activated Hh pathway is not the
primary driver of malignancy. Hh inhibitors have a potential to be a promising drug option, but there
is still much to be learn about the biological effects of Hh pathway inhibition in order to explore the
therapeutic potential of targeting the Hh signaling pathway in OS.
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